
Health Impact Report - Biotechnology & Pharmaceuticals Edition
Description
In our latest quarterly review of corporate sustainability impacts, risks and opportunities, we find that biotechnology and pharmaceutical companies have made substantial ESG commitments. This edition also analyses the effects of government tariffs and trade policy uncertainty on sustainable API sourcing and green manufacturing transitions.
This report analyses thousands of sustainability disclosures from 20 leading entities in the industry, including Johnson & Johnson, Roche Holding and Pfizer. The report now integrates government tariffs and trade policy uncertainty as factors in sustainability disclosures and supply chain risk management.
This report analyses thousands of sustainability disclosures from 20 leading entities in the industry, including Johnson & Johnson, Roche Holding and Pfizer. The report now integrates government tariffs and trade policy uncertainty as factors in sustainability disclosures and supply chain risk management.
Table of Contents
22 Pages
- 1. Nature and climate risks
- 2. Value chain: upstream
- 3. Value chain: downstream
- 4. Planet-Environmental impacts
- 5. People-Social and governance impacts
- 6.UN Sustainable Development Goals
- 7. Technology
- 8. Finance
- 9. Policy
- 10. Calendar of events
- 11. Risks profile
- 12. Industry sustainability highlights
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.